ReviewFrontiers in immunology2026
Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid carcinoma (TC) is the most common cancer of the endocrine system worldwide, and its incidence has remained stable over the past forty years. Complex hormonal and environmental factors influence TC progression. The gut microbiome, a pivotal mediator in maintaining host physiology and the development of pathology, serves as a biomarker and therapeutic target in cancer immunotherapy. The microbiome-assisted tumor microenvironment (TME) sustains tumors through the modulation of multiple mechanisms. Immune suppression in the TME induces a metastatic phenotype of tumor cells by modulating signaling pathways, cell differentiation, and the innate immune response. Current research has confirmed that gut dysbiosis, bacterial outer membrane components (such as lipopolysaccharides and LPS), and metabolites (such as short-chain fatty acids and SCFAs) have bidirectional regulatory effects on thyroid function. However, the role of the local microbiome in modulating treatment responses and its interactions with the immune TME of TC remains unknown. The literature was searched in PubMed, Web of Science, and Google Scholar using keywords associated with "microbiome" and "thyroid carcinoma". Research articles, clinical trials, letters, and meta-analyses were published by January 2026. This narrative review summarizes the role of the intratumor microbiome in tumor progression, interactions with chemotherapy, radiotherapy, and targeted therapies. The associations between the microbiome and the immune TME of cancers, as well as the characteristics of the immune TME and alterations in the gut/intratumor microbiome in patients with TC receiving different therapies, are discussed. Mediating microbiome and metabolites might be potential strategies for optimizing personalized therapeutic interventions against TC. Future research should focus on defining microbial signatures associated with treatment success and developing targeted strategies to improve patient outcomes on the basis of microbiome modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.